Sort
15,273 grants matching “antimicrobial resistance”
Posttranslational Modifications during Natural Product Biosynthesis
$300,120Willem A Van Der Donk · University Of Illinois At Urbana-Champaign · R37 · FY2023 · GM
GENES FOR METHY1-BRANCHED WALL LIPIDS AND TUBERCULOSIS
$300,066University Of Central Florida · R01 · FY2003 · AI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria
$300,001Thomas Joseph Hannan · Fimbrion Therapeutics, Inc. · R43 · FY2025 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** ANTIMICROBIAL RESISTANCE (AMR) IS A SERIOUS PUBLIC HEALTH THREAT. WITH CHICKENS RECOGNIZED AS A RESERVOIR OF AMR BACTERIA, POULTRY PRODUCTS REPRESENT A POTENTIAL SOURCE OF THESE MICROORGANISMS, INCLUDING AMR SALMONELLA. BACTERIA HAVE THE ABILITY TO SHARE GENETIC INFORMATION CRITICAL FOR THEIR SURVIVAL, THEREBY RESULTING IN THE POTENTIAL SPREAD OF AMR DETERMINANTS IN DIVERSE ENVIRONMENTAL NICHES, INCLUDING ANIMAL GUT. HORIZONTAL GENE TRANSFER (HGT) REPRESENTS THE MAJOR ROUTE FOR AMR SPREAD AMONGST BACTERIA, WITH BACTERIAL CONJUGATION CONSTITUTING A COMMON MEANS FOR DISSEMINATION OF AR GENES IN BACTERIA. THEREFORE, THERE IS A CRITICAL NEED FOR MITIGATING AMR GENE SPREAD BYMULTIDRUG RESISTANT FOODBORNE PATHOGENS IN COMMERCIAL BROILER PRODUCTION SYSTEM, THEREBY ENHANCINGFOOD SAFETY AND SAFEGUARDING PUBLIC HEALTH. THE OBJECTIVES OF THE PROPOSAL ARE TO DETERMINE THE EFFECT OF IN-FEED SUPPLEMENTATION OF SELECT PHYTOCHEMICALS (1) IN REDUCING THE HORIZONTAL GENE TRANSFER OF ANTIBIOTIC RESISTANCE GENES FROM MULTIDRUG RESISTANTSALMONELLAHEIDELBERG TO COMMENSAL BACTERIA IN THE CHICKEN GUT, AND (2) TO TRACK THE EFFICACY IN THE REDUCTION OF ANTIBIOTIC RESISTANCE GENE SPREAD AMONG THE GUT BACTERIA USING NEXT GENERATION SEQUENCING TECHNOLOGIES SUCH AS METAGENOMICS AND HI-C SEQUENCING.THIS PROPOSAL REPRESENTS THE FIRST IN-DEPTH STUDY AIMED TO CONTROL AMR TRANSMISSION IN BROILER PRODUCTION SYSTEMS AND IS EXPECTED TO YIELD ENVIRONMENTALLY FRIENDLY STRATEGIES FOR MITIGATING AR SPREAD ACROSS THE FOOD CHAIN.
$300,000University Of Connecticut · · FY2022 · National Institute of Food and Agriculture
Antibiotic Use Data Collection in U.S. Poultry and Swine Production
$300,000Randall S Singer · Mindwalk Consulting Group, Llc · U01 · FY2019 · FD
Stable cationic bacteriochlorins for antimicrobial photodynamic therapy
$300,000Jonathan Sidney Lindsey · Nirvana Pharmaceuticals, Inc. · R41 · FY2007 · AI
FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections
$300,000Laurel McGrane · Fimbrion Therapeutics, Inc. · R43 · FY2023 · AI
Antibiotic Use Data Collection in U.S. Poultry and Swine Production
$300,000Randall S Singer · Mindwalk Consulting Group, Llc · U01 · FY2018 · FD
Treatment of Wound Infection with Novel Uncharged Silver Carbene Complexes
$300,000David J Vachon · Iasis Molecular Sciences, Inc · R43 · FY2012 · AI
Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas Infections
$300,000Michael Einer Hibbing · Fimbrion Therapeutics, Inc. · R43 · FY2025 · AI
Applied Research in Antimicrobial Resistance: Studies of Susceptibility Testing
$300,000Lisa Saiman · Columbia University Health Sciences · R01 · FY2008 · CI
ADVANCING INFECTIOUS DISEASES DETECTION AND RESPONSE IN INDONESIA THROUGH IMPROVING PUBLIC HEALTH LABORATORY CAPACITY
$300,000Agus Suprapto · Kementerian Kesehatan Ri · U01 · FY2019 · GH
Antibiotic Use Data Collection in U.S. Poultry and Swine Production
$300,000Randall S Singer · Mindwalk Consulting Group, Llc · U01 · FY2020 · FD
Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections
$300,000Elke Lipka · Tsrl, Inc. · R41 · FY2018 · AI
A novel Structure Based Vaccine for staphylococcal alpha hemolysin
$300,000Rajan P Adhikari · Integrated Biotherapeutics, Inc. · R43 · FY2012 · AI
Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for Tuberculosis
$300,000Nicholas Jentsch · Fimbrion Therapeutics, Inc. · R43 · FY2025 · AI
Triple action chimera: eradication of nasal S. aureus by cell wall hydrolases
$300,000David Matthew Donovan · U.S. Agricultural Research Center · R01 · FY2009 · AI
Nitric Oxide-Releasing Intranasal Gel To Decolonize Biofilm-embedded S. Aureus
$300,000Susanne Bauman · Novan, Inc. · R43 · FY2011 · AI
Antibiotics for Recalcitrant Infection
$300,000Kenneth Coleman · Arietis · R44 · FY2014 · AI
Novel Antibacterial Scaffold from Natural Products
$300,000Esteban Edward Mena · Lifepharms, Inc. · R43 · FY2011 · AI
Heme Oxygenase: Structure, function and pathogenesis
$300,000Angela None Wilks · University Of Maryland Baltimore · R56 · FY2009 · AI
Enhanced Efficacy Photodynamic Disinfection
$300,000Sanjiv Lalwani · Lynntech, Inc. · R43 · FY2014 · AI
Molecular bases of DAP-resistance-mediated sensitization to beta-lactams in MRSA
$300,000Adriana E Rosato · Methodist Hospital Research Institute · R56 · FY2014 · AI
In vivo Testing of S. aureus alpha-Hemolysin Inhibitors
$300,000Vladimir A Karginov · Innovative Biologics, Inc · R43 · FY2009 · AI
SQ109 for treatment of MDR-TB
$300,000Leo Einck · Sequella, Inc. · R43 · FY2010 · AI